Short Interest in Celularity Inc. (NASDAQ:CELU) Increases By 7.1%

Celularity Inc. (NASDAQ:CELU) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 415,800 shares, a growth of 7.1% from the March 15th total of 388,300 shares. Based on an average daily trading volume, of 253,600 shares, the days-to-cover ratio is presently 1.6 days. Approximately 3.9% of the company’s shares are short sold.

Hedge Funds Weigh In On Celularity

Several institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC grew its position in shares of Celularity by 28.3% in the 1st quarter. Jane Street Group LLC now owns 16,813 shares of the company’s stock valued at $146,000 after purchasing an additional 3,713 shares during the period. Citigroup Inc. bought a new stake in Celularity in the 1st quarter valued at approximately $36,000. UBS Group AG lifted its stake in Celularity by 177.6% in the 2nd quarter. UBS Group AG now owns 10,300 shares of the company’s stock valued at $36,000 after acquiring an additional 6,590 shares in the last quarter. American International Group Inc. bought a new stake in Celularity in the 2nd quarter valued at approximately $25,000. Finally, JPMorgan Chase & Co. bought a new stake in Celularity in the 2nd quarter valued at approximately $28,000. 19.02% of the stock is currently owned by institutional investors and hedge funds.

Celularity Trading Down 16.7 %

Shares of CELU opened at $3.50 on Wednesday. The stock has a 50 day simple moving average of $4.81 and a 200 day simple moving average of $3.27. Celularity has a 52-week low of $1.59 and a 52-week high of $8.90.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.